ANDA 91555, held by Teva Pharms USA. Eptifibatide.
As of Nov 14, 2026, ANDA 91555 (Eptifibatide), held by Teva Pharms USA, was first approved by FDA on Jun 5, 2015, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 5, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Eptifibatide75MG/100ML ยท injectable;injection | Eptifibatide | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
